Copyright
©The Author(s) 2021.
World J Crit Care Med. Sep 9, 2021; 10(5): 220-231
Published online Sep 9, 2021. doi: 10.5492/wjccm.v10.i5.220
Published online Sep 9, 2021. doi: 10.5492/wjccm.v10.i5.220
Antimicrobial agent | Acinetobacter baumanii | Pseudomonas aeruginosa | Escherichia coli | Klebsiella |
n (%) = 5 (15) | n (%) = 4 (12) | n (%) = 4 (12) | n (%) = 3 (9) | |
Piperacillin tazobactam | 2/5 (40) | 4/4 (100) | ||
Ceftriaxone | 1/4 (25) | 1/3 (33) | ||
Ceftazidime | 2/5 (40) | 4/4 (100) | 1/4 (25) | 1/3 (33) |
Cefipime | 2/5 (40) | 4/4 (100) | 1/4 (25) | 1/3 (33) |
Merpenem | 2/5 (40) | 4/4 (100) | 2/4 (50) | 1/3 (33) |
Imipenem | 2/5 (40) | 2/4 (50) | 2/4 (50) | 1/3 (33) |
Ciprofloxacin | 2/5 (40) | 4/4 (100) | 1/4 (25) | 1/3 (33) |
Gentamicin | 2/5 (40) | 4/4 (100) | 1/4 (25) | 1/3 (33) |
Amikacin | 2/5 (40) | 4/4 (100) | 1/4 (25) | 1/3 (33) |
Colistin | 5/5 (100) | 4/4 (100) | 4/4 (100) | 3/3 (100) |
- Citation: Al-Khawaja S, Saeed NK, Al-khawaja S, Azzam N, Al-Biltagi M. Trends of central line-associated bloodstream infections in the intensive care unit in the Kingdom of Bahrain: Four years’ experience. World J Crit Care Med 2021; 10(5): 220-231
- URL: https://www.wjgnet.com/2220-3141/full/v10/i5/220.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v10.i5.220